John Schieszer, MA

Contributing Writer https://www.cancertherapyadvisor.com

John Schieszer is an award winning medical journalist who produces The Medical Minute podcasts. John received his BA in journalism from the University of Missouri-Columbia School of Journalism and his MA in english from the University of Missouri-St. Louis. In 1990, John was awarded the Case Western Reserve University School of Medicine’s Third Annual Fellowship for Journalists in Biomedical Research. In 1992, he completed a Medical Fellowship at the Marine Biological Laboratories in Woods Hole, Massachusetts.

All articles by John Schieszer, MA

$Hypofractionated radiotherapy’s role in postoperative settings remains unclear and awaits outcomes f$

General Oncology

A Closer Look at Reporting Toxicities in Cancer Clinical Trials

John Schieszer, MA

January 31, 2019

QoL for patients with cancer is reduced just as much by the accumulation of low-level toxicities as it is from high-level adverse events.

Sarcoma

mTOR Inhibition May Benefit Some Sarcoma Patients

John Schieszer, MA

December 21, 2018

mTOR inhibition is thought to enhance the efficacy of chemotherapy.

Patients with locally advanced or metastatic renal cell carcinoma randomly assigned to receive pazop

Sarcoma

Induction ILP Prior to Surgery for ESTS Did Not Improve Patient Outcomes Compared With Standard of Care

John Schieszer, MA

December 21, 2018

The outcomes of patients with ESTS did not improve as a result of induction ILP prior to surgical intervention.

Chronic Lymphocytic Leukemia

Fixed Duration of Venetoclax-Rituximab for CLL May Prolong Survival

John Schieszer, MA

December 20, 2018

When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.

Efforts are underway to develop predictive molecular biomarkers that can improve patient selection f

Lung Cancer

Analysis of Durvalumab Consolidation Therapy Costs in Stage III NSCLC

John Schieszer, MA

December 20, 2018

Use of durvalumab consolidation therapy in all eligible patients with NSCLC was deemed cost-effective, despite its incremental budgetary consequence of $768 million in year 1.

While a recent discovery of a series of communicable cancers has raised concerns, there has been no

Prostate Cancer

Hypofractionated Radiotherapy May Benefit Patients With Localized Prostate Cancer

John Schieszer, MA

December 19, 2018

A study suggests HIMRT may have some advantages over CIMRT for treating men with localized prostate cancer.

Bladder Cancer

FCT Compared With GD for Muscle-Invasive Bladder Cancer

John Schieszer, MA

December 17, 2018

An established chemoradiation regimen is compared with gemcitabine and once-daily radiation in the selective bladder-sparing treatment of muscle-invasive bladder cancer.

The gene expression-based prognostic model, RHL30, has the potential to provide insights for the sel

Bladder Cancer

Frailty Assessment May Benefit Patients Undergoing Radical Cystectomy

John Schieszer, MA

December 17, 2018

Older patients should be routinely assessed prior to radical cystectomy to guide both
preoperative and postoperative care.

Many agents are in ongoing trials, and may provide additional options for patients with metastatic H

Breast Cancer

Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI

John Schieszer, MA

December 13, 2018

Researchers reported that 3 years after whole-breast irradiation and a tumor bed boost, outcomes with hypofractionation and conventional fractionation are similar.